Please login to the form below

Not currently logged in
Email:
Password:

Libtayo

This page shows the latest Libtayo news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi is a bit of a latecomer to the cancer immunotherapy category but claimed approval earlier this year for  Libtayo(cemiplimab) – the sixth PD-1/PD-L1 inhibitor to reach the

Latest news

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics